Histopathology of Small Intestine Induced by Cisplatin in Male Wistar Rats


  • Sarawoot PALIPOCH School of Medicine, Walailak University, Nakhon Si Thammarat 80161
  • Chuchard PUNSAWAD School of Medicine, Walailak University, Nakhon Si Thammarat 80161
  • Dutsadee CHINNAPUN School of Medicine, Walailak University, Nakhon Si Thammarat 80161
  • Prasit SUWANNALERT Department of Pathobiology, Faculty of Science, Mahidol University, Bangkok 10400


Pathology, toxicology, small intestine, cisplatin


Cisplatin, cis-diamminedichloroplatinum (II) is a highly effective drug used to treat several cancers. Unfortunately, it has various clinical side effects affecting many tissues. However, small intestine toxicity induced by cisplatin has been rare reports to date. This study aims to investigate the pathology of small intestine upon cisplatin treatment at various doses using histological techniques. Male Wistar rats were divided into 5 groups: group 1 was intraperitoneally (IP) injected with normal saline; group 2, 3, 4 and 5 were IP injected with cisplatin at doses of 25, 50, 75 and 100 mg/kg body weight (BW), respectively. On day 3, rats were weighed and small intestines were collected. This study found that cisplatin significantly reduces BW at all concentrations compared to saline group. Histological analysis of small intestine induced by cisplatin illustrating various pathologies includes hemodynamic change (hemorrhage), reversible injuries (distortion of mucosal architecture, development of subepithelial space and lifting of epithelial layer from the lamina propria) and irreversible injuries (degenerative changes of villi, sloughing of necrotic villi into intestinal lumina and loss of villi). Additionally, cellular adaptations were also elicited including hyperplasia of lamina propria and columnar epithelium lining villi and atrophy of villi. In conclusion, cisplatin administrations lead to pathologies of small intestine, consequently causing weight loss whose severity depends on its concentrations.


Download data is not yet available.


Metrics Loading ...


BH Ali and MS Al Moundhri. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: A review of some recent research. Food Chem.Toxicol. 2006; 44, 1173-83.

BA Chabner, J Bertino, J Cleary, T Ortiz, A Lane, J Supko and D Ryan. Cytotoxic Agents. In: LL Brunton, BA Chabner and BC Knollmann (eds.). Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th (ed.). The McGraw-Hill Companies, 2011.

Y Li, RB Womer and JH Silber. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur. J. Cancer 2004; 40, 2445-51.

JG Zhang and WE Lindup. Cisplatin nephrotoxicity: Decreases in mitochondrial protein sulphydryl concentration and calcium uptake by mitochondria from rat renal cortical slices. Biochem. Pharmacol. 1994; 47, 1127-35.

M Nazıroǧlu, A Karaoğlu and AO Aksoy. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology 2004; 195, 221-30.

Y Miyamoto and M Miyamoto. Immunohistochemical localizations of secretin, cholecystokinin, and somatostatin in the rat small intestine after acute cisplatin treatment. Exp. Mol. Pathol. 2004; 77, 238-45.

NA Arivarasu, S Fatima and R Mahmood. Effect of cisplatin on brush border membrane enzymes and anti-oxidant system of rat intestine. Life Sci. 2007; 81, 393-8.

A Tavakkolizadeh, EE Whang, SW Ashley and MJ Zinner. Small Intestine. In: FC Brunicardi, DK Andersen, TR Billiar, DL Dunn, JG Hunter, JB Matthews and RE Pollock (eds.). Schwartz's Principles of Surgery. 9th (ed.). The McGraw-Hill Companies, 2010.

NA Arivarasu, S Priyamvada and R Mahmood. Oral administration of caffeic acid ameliorates the effect of cisplatin on brush border membrane enzymes and antioxidant system in rat intestine. Exp. Toxicol. Pathol. 2013; 65, 21-5.

B Chang, M Nishikawa, E Sato, K Utsumi and M Inoue. L-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine. Arch. Biochem. Biophys. 2002; 405, 55-64.

CP Bearcroft, P Domizio, FH Mourad, EA Andre and MJ Farthing. Cisplatin impairs fluid and electrolyte absorption in rat small intestine: a role for 5-hydroxytryptamine. Gut. 1999; 44, 174-9.

Z Zeino, G Sisson and I Bjarnason. Adverse effects of drugs on small intestine and colon. Best Pract. Res. Cl. Ga. 2010; 24, 133-41.

K Moriyama, Y Kouchi, H Morinaga, K Irimura, T Hayashi, A Ohuchida, T Goto and Y Yoshizawa. Diamine oxidase, a plasma biomarker in rats to GI tract toxicity of oral fluorouracil anti-cancer drugs. Toxicology 2006; 217, 233-9.

FD Lee. Drug-related intestinal disease. Curr. Diagn. Pathol. 1997; 4, 128-34.

NJ Wadd, C Tiplady and JT Roberts. Cisplatin and acute tubular necrosis. Clin. Oncol. 1997; 9, 267-8.




How to Cite

PALIPOCH, S., PUNSAWAD, C., CHINNAPUN, D., & SUWANNALERT, P. (2013). Histopathology of Small Intestine Induced by Cisplatin in Male Wistar Rats. Walailak Journal of Science and Technology (WJST), 10(6), 657–663. Retrieved from https://wjst.wu.ac.th/index.php/wjst/article/view/689

Most read articles by the same author(s)